Direct
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹148 Cr
Expense Ratio
0.51%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+41.62%
— (Cat Avg.)
3 Years
+15.75%
— (Cat Avg.)
Since Inception
+20.36%
— (Cat Avg.)
Equity | ₹148.16 Cr | 99.81% |
Others | ₹0.28 Cr | 0.19% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹20.29 Cr | 13.67% |
Cipla Ltd | Equity | ₹9.96 Cr | 6.71% |
Dr Reddy's Laboratories Ltd | Equity | ₹9.69 Cr | 6.53% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.82 Cr | 5.94% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.19 Cr | 5.51% |
Divi's Laboratories Ltd | Equity | ₹7.23 Cr | 4.87% |
Eli Lilly and Co | Equity | ₹6.94 Cr | 4.68% |
Lupin Ltd | Equity | ₹5.36 Cr | 3.61% |
Aurobindo Pharma Ltd | Equity | ₹4.65 Cr | 3.13% |
Novo Nordisk A/S ADR | Equity | ₹4.62 Cr | 3.11% |
Johnson & Johnson | Equity | ₹4.06 Cr | 2.74% |
Torrent Pharmaceuticals Ltd | Equity | ₹3.96 Cr | 2.67% |
AbbVie Inc | Equity | ₹3.5 Cr | 2.36% |
Merck & Co Inc | Equity | ₹3.06 Cr | 2.06% |
Fortis Healthcare Ltd | Equity | ₹3.03 Cr | 2.04% |
Glenmark Pharmaceuticals Ltd | Equity | ₹2.55 Cr | 1.72% |
Thermo Fisher Scientific Inc | Equity | ₹2.5 Cr | 1.69% |
Mankind Pharma Ltd | Equity | ₹2.5 Cr | 1.68% |
Novartis AG ADR | Equity | ₹2.35 Cr | 1.58% |
Ipca Laboratories Ltd | Equity | ₹2.24 Cr | 1.51% |
Danaher Corp | Equity | ₹2.08 Cr | 1.40% |
Laurus Labs Ltd | Equity | ₹2 Cr | 1.35% |
Abbott Laboratories | Equity | ₹1.96 Cr | 1.32% |
Amgen Inc | Equity | ₹1.9 Cr | 1.28% |
Biocon Ltd | Equity | ₹1.86 Cr | 1.25% |
Syngene International Ltd | Equity | ₹1.8 Cr | 1.21% |
Intuitive Surgical Inc | Equity | ₹1.68 Cr | 1.13% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.65 Cr | 1.11% |
Gland Pharma Ltd | Equity | ₹1.52 Cr | 1.02% |
Ajanta Pharma Ltd | Equity | ₹1.46 Cr | 0.98% |
Dr. Lal PathLabs Ltd | Equity | ₹1.43 Cr | 0.96% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.42 Cr | 0.96% |
Vertex Pharmaceuticals Inc | Equity | ₹1.37 Cr | 0.92% |
Suven Pharmaceuticals Ltd | Equity | ₹1.25 Cr | 0.84% |
Global Health Ltd | Equity | ₹1.23 Cr | 0.83% |
Stryker Corp | Equity | ₹1.2 Cr | 0.81% |
Medtronic PLC | Equity | ₹1.14 Cr | 0.77% |
Narayana Hrudayalaya Ltd | Equity | ₹1.1 Cr | 0.74% |
Gilead Sciences Inc | Equity | ₹1.01 Cr | 0.68% |
Pfizer Ltd | Equity | ₹0.95 Cr | 0.64% |
Becton Dickinson & Co | Equity | ₹0.74 Cr | 0.50% |
IQVIA Holdings Inc | Equity | ₹0.48 Cr | 0.32% |
Agilent Technologies Inc | Equity | ₹0.44 Cr | 0.30% |
Moderna Inc | Equity | ₹0.42 Cr | 0.28% |
Sanofi Consumer He | Equity | ₹0.36 Cr | 0.24% |
Illumina Inc | Equity | ₹0.21 Cr | 0.14% |
Net Receivables/(Payables) | Cash - Collateral | ₹0.17 Cr | 0.11% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.11 Cr | 0.07% |
GRAIL Inc | Equity | ₹0 Cr | 0.00% |
Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
41.64%
Mid Cap Stocks
24.12%
Small Cap Stocks
5.73%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹147.8 Cr | 99.57% |
Standard Deviation
This fund
13.85%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.75
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021
Since February 2021
ISIN | INF754K01LV5 | Expense Ratio | 0.51% | Exit Load | No Charges | Fund Size | ₹148 Cr | Age | 26 Oct 2020 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹539.42 Cr | 45.5% |
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹539.42 Cr | 44.6% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹397.46 Cr | 61.6% |
SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹587.30 Cr | 42.9% |
DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1683.73 Cr | 39.1% |
SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1000.66 Cr | 49.6% |
SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹587.30 Cr | 43.7% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹397.46 Cr | 62.6% |
DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1683.73 Cr | 39.9% |
SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1000.66 Cr | 48.7% |
Total AUM
₹1,62,381 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk